• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Incannex Healthcare Inc. - Common Stock (NQ: IXHL )

    2.270 -0.130 (-5.42%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Incannex Healthcare Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 Next >
    Incannex Secures $60M Financing To Drive Advances In Psychedelic And Cannabinoid Therapies
    Incannex Healthcare secures $60M in financing from Arena Investors to support clinical trials for cannabinoid and psychedelic therapies. 
    Via Benzinga
    FDA Clears Incannex To Proceed With Phase 2 Psilocybin-Assisted Therapy Trial For Anxiety
    FDA approves Incannex's Phase 2 trial for psilocybin-assisted psychotherapy in treating generalized anxiety disorder, following a successful review of the IND application. 
    Via Benzinga
    Exposures Product Safety
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    We have the biggest pre-market stock movers that investors are going to want to start the trading week with on Monday morning! 
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning! 
    Via InvestorPlace
    FDA Experts Weigh In On Incannex's CannQuit-O With Feedback On CBD As Treatment For Opioid Use Disorder
    Incannex Healthcare Inc., a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of a pre-investigational new drug meeting with the U.S. Food and Drug... 
    Via Benzinga
    Exposures Product Safety
    Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
    Via Benzinga
    Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD
    The 5 constituents in the Psychedelic Compound-Based Drug Stocks Index were up 10.0%, on average, last week and are now up 53.9% YTD. 
    Via Talk Markets
    March Recap: Largest Psychedelic Drug Stocks Up Another 5%
    The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 5.4%, on average, in March and are now UP 39.9% YTD. 
    Via Talk Markets
    Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
    Via Benzinga
    Psychedelic-Assisted Therapy Advancements Create A New Horizon For Mental Health In Colorado
    Psilocybin-assisted therapy shows promise in treating GAD. Denver trains first responders in psychedelic crisis intervention. Heroic Hearts Project supports veterans with PTSD through legal psychedelic... 
    Via Benzinga
    Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week
    The FDA has granted breakthrough designation to Mind Medicine's program for the treatment of generalized anxiety disorder. 
    Via Talk Markets
    Exposures Product Safety
    Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
    Via Benzinga
    Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD
    The Psychedelic Compound-Based Drug Stocks Index was up 15.0% in February led by Incannex Healthcare which was up 55.1%. 
    Via Talk Markets
    Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety
    Via Benzinga
    What's Going On With Incannex Stock?
    Incannex said that its Phase 2 Psi-GAD1 clinical trial of psilocybin in generalized anxiety disorder met its primary endpoint of demonstrating a large clinical effect in the psilocybin treatment group... 
    Via Benzinga
    How I Swing Trade Via Strength With Recent Examples
    In this video, I explain how I avoid major losses, keep my losses small, and maximize gains. I also provide some recent trades as examples. 
    Via Talk Markets
    Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results. 
    Via Benzinga
    Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex
    IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the U.S. Food and Drug Administration regarding the development of CannQuit-N for tobacco smoking... 
    Via Talk Markets
    Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
    Via Benzinga
    Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
    Via Benzinga
    5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week
    The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD. 
    Via Talk Markets
    Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
    New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian... 
    Via Benzinga
    Podcast: International Cannabis And Psychedelics Co. Is Working 'Hand In Hand' With FDA To Forge New Therapy Frontiers
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis Product Safety
    5 Largest Psychedelic Drug Stocks Advanced Slightly Last Week
    The munKNEE Psychedelic Drug Stocks Index went up 2.3% last week and is now up 1.8% MTD. 
    Via Talk Markets
    Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
    Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD 
    Via Benzinga
    Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
    Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury 
    Via Benzinga
    Global Mofy Metaverse Reports Follow-on Offering, Joins Lyft, Coinbase Global And Other Big Stocks Moving Lower On Friday
    U.S. stocks traded mixed, with the Nasdaq Composite falling around 0.3% on Friday. Shares of Global Mofy Metaverse Limited (NASDAQ: GMM) shares fell sharply during Friday’s session after the company... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
    President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also... 
    Via Benzinga
    Psychedelic Drug Stocks Index Up In December; Down YTD
    The constituents in the Index are up 9.1% MTD, on average, are down 29.2% YTD, on average, and are now down 85.9% from their highs in 2021. 
    Via Talk Markets
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.